- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2011-10-1 01:25 编辑
http://www.marketwatch.com/story/bristol-myers-squibb-to-present-new-data-demonstrating-companys-leadership-in-liver-disease-at-the-liver-meetingr-aasld-annual-meeting-2011-09-30
Bristol-Myers Squibb to Present New Data Demonstrating Company's Leadership in Liver Disease at The Liver Meeting(R) / AASLD Annual Meeting Oral presentation on BARACLUDE(R) (entecavir) reinforces continued clinical development commitment in hepatitis B施贵宝公司的领导在肝病肝会议
/肝病学会年度会议提出新的数据表明对BARACLUDE(R)恩替卡韦)的口头陈述,
加强继续在B型肝炎的临床发展的承诺
Abstract Number Title Date/Time
--------------- -------------------------------------------------------------------- ------------------------
Hepatitis B: BARACLUDE Clinical Data
------------------------------------------------------------------------------------------------------------------
Oral Entecavir (ETV) monotherapy for 96 weeks is comparable to Presidential Plenary III
#223 combination therapy with ETV plus tenofovir (TDF) in Nov. 8
nucleos(t)ide-naive patients with chronic hepatitis B (CHB): the 8:00 am PST
BE-LOW study
--------------- -------------------------------------------------------------------- ------------------------
Hepatitis B: Outcomes Research / Real-World Data ------------------------------------------------------------------------------------------------------------------
Poster Real World Data on Long Term Treatment Initiation in patients with Nov. 5
#458 Chronic Hepatitis B: cohort observations in France, Germany, Poland,
Romania and Turkey
--------------- -------------------------------------------------------------------- ------------------------
Poster Cost-effectiveness of entecavir versus adefovir for the treatment of Nov. 5
#478 chronic hepatitis B in patients with decompensated cirrhosis
--------------- -------------------------------------------------------------------- ------------------------
Poster Treatment Patterns, Health Care Use, and Costs associated with Nov. 5
#481 First-Line Treatment for Chronic Hepatitis B with Entecavir versus
Tenofovir
--------------- -------------------------------------------------------------------- ------------------------
Poster Treatment Patterns, Health Care Use, and Costs associated with Nov. 5
#482 First-Line Treatment for Chronic Hepatitis B with Oral Antivirals
Recommended by Current Guidelines versus Oral Antivirals Not
Recommended by Current Guidelines |
|